| Completed | 3 | 821 | Europe, US, RoW | Interferon beta-1a, Rebif, Ocrelizumab-matching placebo, Ocrelizumab, RO4964913, Interferon beta-1a-matching placebo | Hoffmann-La Roche | Relapsing Multiple Sclerosis | 04/15 | 12/22 | | |
| Completed | 3 | 835 | Europe, Canada, US, RoW | Interferon beta-1a, Rebif, Ocrelizumab-matching placebo, Ocrelizumab, RO4964913, Interferon beta-1a-matching placebo | Hoffmann-La Roche | Relapsing Multiple Sclerosis | 05/15 | 12/22 | | |
2020-002060-31: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care Mezinárodní randomizovaná studie další léčby COVID-19 u hospitalizovaných pacientů, kteří jsou léčeni standardní péčí. |
|
|
| Ongoing | 3 | 100000 | Europe | remdesivir, Lyophilisate for solution for infusion, Coated tablet, Powder and solution for solution for injection, Kaletra, Rebif, Plaquenil | Masaryk University, World Health Organisation, Masaryk University | COVID-19 COVID-19, COVID-19 COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
NCT03283397: A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS |
|
|
| Recruiting | 3 | 400 | RoW | EK-12, INF beta-1a | Bosnalijek D.D, MonitorCRO | Multiple Sclerosis, Relapsing-Remitting | 12/23 | 07/24 | | |
